News

NICE to consider lenalidomide maintenance treatment for myeloma patients post high dose therapy and stem cell transplantation

Lenalidomide (Revlimid®) maintenance for myeloma patients who have undergone high dose therapy and stem cell transplantation (HDT-SCT) will be considered for use on the NHS by The National Institute for Health and Care Excellence (NICE) later this year. This announcement comes after updated advice from the manufacturer Celgene and follows publication of data from the Myeloma XI clinical…

Details

Myeloma UK is helping to Make Blood Cancer Visible this September

Myeloma UK is helping to Make Blood Cancer Visible in September. The campaign, in partnership with Janssen Oncology and eight patient organisations, marks Blood Cancer Awareness Month. It will feature a public art installation, which will help visitors to understand the experiences of people affected by blood cancer.   The installation is made up of…

Details